Amgen, amid $10B fight with IRS, lands in Senate committee's tax probe

The Senate Finance Committee’s probe into U.S. drugmakers’ tax practices has intensified, as Amgen—already embroiled in an Internal Revenue Service (IRS) investigation over the transfer of U.S. profits to Puerto Rico—now finds itself in the crosshairs of the committee’s chair, Senator Ron Wyden.